Literature DB >> 3681898

Thromboxane synthetase inhibitors and antihypertensive agents. 4. N-[(1H-imidazol-1-yl)alkyl] derivatives of quinazoline-2,4(1H,3H)-diones, quinazolin-4(3H)-ones, and 1,2,3-benzotriazin-4(3H)-ones.

W B Wright1, A S Tomcufcik, P S Chan, J W Marsico, J B Press.   

Abstract

The quinazolinedione, quinazolinone, and 1,2,3-benzotriazinone title compounds were prepared as analogues of N-[(1H-imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones which were the subject of a previous report from our laboratories. These compounds were evaluated as thromboxane (TX) synthetase inhibitors and as antihypertensive agents. While each series of compounds had activity both as TX synthetase inhibitors and as antihypertensives, the best compounds were N-[(1H-imidazol-1-yl)alkyl]quinazoline-2,4(1H,3H]-diones (V). In general these compounds were all selective enzyme inhibitors at least equipotent with the standard dazoxiben. These compounds were also very active antihypertensive agents as determined in SHR. The SAR is discussed for both types of activity. Compound 20a was further evaluated for TX formation inhibiting properties in several other platelet types both in vitro and ex vivo and is between 100 and 1000 times more potent than dazoxiben.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3681898     DOI: 10.1021/jm00395a016

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Synthesis and Antimicrobial Screening of Pyrazolo-3-Aryl Quinazolin-4(3H)ones.

Authors:  M B Deshmukh; S Patil; S S Patil; S D Jadhav
Journal:  Indian J Pharm Sci       Date:  2010-07       Impact factor: 0.975

2.  SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Konstantina Fylaktakidou; Efthimios Sivridis; Christos E Zois; Dimitra Kalamida; Achilleas Mitrakas; Stamatia Pouliliou; Ilias V Karagounis; Konstantinos Simopoulos; David J P Ferguson; Adrian L Harris
Journal:  Invest New Drugs       Date:  2018-01-31       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.